Biotech Industry News 22 December 2025

Legend Biotech stock hits a fresh 52-week low as biotech lags — JPMorgan update looms

New York, January 5, 2026, 15:53 EST — Regular session Legend Biotech Corp (LEGN) shares fell 4.7% to $20.49 on Monday, after touching $20.29 — a fresh 52-week low — in afternoon trading. The stock is about 55% below its

5 January 2026

Biotech Industry·Financial Analysis·Investment News·Stock Market

Outlook Therapeutics stock drops after FDA issues another Lytenava CRL for wet AMD

NEW YORK, January 1, 2026, 04:59 ET — Market closed Outlook Therapeutics, Inc. (Nasdaq: OTLK) shares fell sharply in after-hours trading on Dec. 31 after the U.S. Food and Drug Administration again declined to approve its ONS-5010/LYTENAVA (bevacizumab-vikg) filing for

1 January 2026

Biotech Industry·FDA News·Pharmaceuticals·Stock Market

Corcept Therapeutics stock tanks 50% after FDA relacorilant setback — what’s next for CORT

NEW YORK, January 1, 2026, 04:13 ET — Market closed Corcept Therapeutics Incorporated shares last closed down 50.4% at $34.80 on Wednesday. Yahoo Finance The selloff followed news that the U.S. drug regulator will not approve relacorilant in its current

1 January 2026

Biotech Industry·FDA News·Investment Analysis·Pharmaceuticals·Stock Market

Why Travere Therapeutics (TVTX) stock is down today as insider sales hit the tape ahead of a key FDA date

NEW YORK, December 30, 2025, 15:16 ET — Regular session Travere Therapeutics Inc shares were down about 3.8% at $37.39 on Tuesday afternoon, extending losses after recent insider-trading disclosures. The stock traded between $37.27 and $39.20, with about 893,000 shares

30 December 2025

Biotech Industry·FDA Approvals·Insider Trading·Investment Analysis·Stock Market News

Why Cogent Biosciences stock is down today after its FDA filing for bezuclastinib

NEW YORK, December 30, 2025, 14:40 ET — Regular session Shares of Cogent Biosciences, Inc. fell 2.7% to $36.88 on Tuesday after the biotech said it submitted a New Drug Application to the U.S. Food and Drug Administration for its

30 December 2025

Biotech Industry·FDA News·Investment Analysis·Pharmaceuticals·Stock Market

ADMA Biologics stock slides nearly 4% as biotech weakens in thin year-end trade

NEW YORK, December 30, 2025, 13:35 ET — Regular session Shares of ADMA Biologics fell 3.7% to $18.40 in afternoon trading on Tuesday, a steeper drop than the broader biotech group. The SPDR S&P Biotech ETF was down about 1.3%.

30 December 2025

Biotech Industry·Financial Analysis·Investment News·Stock Market

Merck & Co. (MRK) Enters 2026 in the Spotlight: BMO Upgrade to $130, FDA Fast-Track Vouchers and TrumpRx Pricing Deal Reframe the Post-Keytruda Story

December 25, 2025 — Even with U.S. markets closed for Christmas Day, Merck & Co., Inc. (NYSE: MRK) is ending 2025 as one of the most-watched large-cap pharma names on Wall Street. The stock closed at $106.45 on Wednesday, Dec.

25 December 2025

Biotech Industry·Drug Pricing·FDA Approvals·Pharmaceuticals

Merck (MRK) Stock News on Dec. 25, 2025: BMO Lifts Target to $130 as FDA Fast-Track Vouchers and Keytruda Data Fuel Momentum

December 25, 2025 — Merck & Co., Inc. (NYSE: MRK) is ending 2025 with something investors tend to enjoy: momentum with a story behind it. Even with U.S. markets closed for Christmas Day, Merck shares are in focus after a

25 December 2025

Biotech Industry·FDA News·Investment Insights·Pharmaceuticals·Stock Market

Recursion Pharmaceuticals (RXRX) Stock News Today: Analysts Refocus on REC-4881 Data, ARK Buying, and a 2026 CEO Transition

Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) is ending 2025 with something investors in AI-driven biotech rarely get in the same month: fresh clinical momentum, a high-profile Wall Street upgrade, and renewed attention from Cathie Wood’s ARK funds—all playing out during a

24 December 2025

Analyst Reports·Biotech Industry·Pharmaceuticals·Stock News

Dynavax Technologies (DVAX) Stock Jumps on Sanofi’s $2.2B Cash Buyout Offer: Latest News, Forecasts, and What Comes Next (Dec. 24, 2025)

Dynavax Technologies Corporation (NASDAQ: DVAX) is the center of the biotech tape on Wednesday, December 24, 2025, after Sanofi announced a deal to acquire the vaccine maker in an all-cash transaction valued at roughly $2.2 billion. The headline number investors

24 December 2025

Biotech Industry·Financial Forecasts·Investment Analysis·Mergers and Acquisitions·Stock Market News

Biogen (BIIB) Stock News Today (Dec. 22, 2025): QALSODY Data, Nasdaq-100 Exit, and Analyst Forecasts

Biogen Inc. (NASDAQ: BIIB) is in focus on Monday, December 22, 2025—a day that combines company-specific clinical headlines with a major index event for the stock. Investors are weighing fresh long‑term data for QALSODY (tofersen) in a rare genetic form

22 December 2025

Analyst Ratings·Biotech Industry·Earnings Reports·Nasdaq Updates·Stock Market News

Amicus Therapeutics (FOLD) Stock Today: BioMarin’s $14.50 Cash Buyout, Analyst Downgrades, and What Investors Watch Next (Dec. 22, 2025)

Amicus Therapeutics, Inc. (NASDAQ: FOLD) is trading like a classic “deal stock” on December 22, 2025—hovering just below a fixed cash acquisition price after BioMarin Pharmaceutical (NASDAQ: BMRN) agreed to buy the company in an all-cash transaction. As of the

22 December 2025

Biotech Industry·Financial Updates·Investment Analysis·Mergers and Acquisitions·Stock Market News

Biotech Industry News 22 December 2025 - 5 January 2026